Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma Inc. (Nasdaq: EPIX) announced that multiple abstracts on its clinical candidate, EPI-7386, have been accepted for presentation at significant medical events. Notable presentations include the 27th Annual Prostate Cancer Foundation Scientific Retreat on October 20, and the 32nd EORTC-NCI-AACR Symposium on October 24, 2020. EPI-7386, a potent androgen receptor inhibitor, is in development for treating prostate cancer, particularly in patients resistant to existing therapies. The data presented may further characterize its preclinical profile and efficacy.
ESSA Pharma Inc. (Nasdaq: EPIX) announced its participation in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 11:40 am Eastern. Dr. David R. Parkinson, CEO, will present a corporate overview, with key executives available for one-on-one meetings. The presentation will be webcast live, with a replay available for 90 days on ESSA's website. ESSA focuses on developing therapies for castration-resistant prostate cancer and recently filed an IND for EPI-7386.
ESSA Pharma Inc. (Nasdaq: EPIX) presented data on its clinical candidate, EPI-7386, at the ESMO Virtual Congress 2020. The study demonstrated that EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor, provides superior inhibition of AR-associated activity when combined with existing therapies like enzalutamide, apalutamide, and darolutamide. These findings support further exploration of EPI-7386 in earlier lines of prostate cancer treatment. Currently, the company is conducting a Phase 1 study of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC).
ESSA Pharma Inc. (NASDAQ: EPIX) announced that the FDA granted Fast Track Designation to EPI-7386, its oral androgen receptor inhibitor, for treating metastatic castration-resistant prostate cancer (mCRPC) resistant to standard treatments. This designation acknowledges the urgent need for effective therapies in mCRPC patients. It facilitates expedited development and review processes, including eligibility for accelerated approval and rolling review of the New Drug Application. The Phase 1 clinical trial for EPI-7386 is set to enroll 18 mCRPC patients, assessing its safety and anti-tumor efficacy.
ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI) is set to present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, and the Cantor Fitzgerald Global Healthcare Conference 2020 on September 17, 2020. CEO Dr. David R. Parkinson will provide a corporate overview and engage in a fireside chat. The presentations will be available for live streaming on their Investor Relations page and can be replayed for 90 days. ESSA focuses on novel therapies for prostate cancer, particularly for patients with castration-resistant prostate cancer.
ESSA Pharma Inc. (NASDAQ: EPIX) reported a net loss of $4.9 million for the fiscal third quarter ended June 30, 2020, compared to a $3.3 million loss in the same period in 2019. The increase in loss is attributed to higher R&D and G&A expenditures, including $1.5 million in non-cash share-based payments. The company completed a public offering raising $48.99 million to support ongoing clinical trials for EPI-7386, which commenced dosing the first patient in July. As of June 30, 2020, cash on hand was $36.5 million.
ESSA Pharma Inc. (Nasdaq: EPIX) announced the completion of a public offering of 7,100,000 common shares at a price of US$6.00 per share, raising approximately US$42.6 million. Following the exercise of an underwriters' option, the total proceeds reached US$45.0 million after expenses. The funds will support clinical and pre-clinical studies, particularly for EPI-7386, and further investments in the Company’s pipeline, ensuring cash resources through 2023. Major investors included Pfizer and several capital firms.
ESSA Pharma announced a public offering of 7,100,000 common shares at US$6.00 each, raising approximately US$42.6 million. After fees, the net proceeds are expected to be around US$39.0 million. Funds will be allocated to pre-clinical and clinical activities, manufacturing, research, and general corporate purposes. Jefferies leads the offering, with Oppenheimer & Co. and Bloom Burton Securities as co-managers. The offering is set to close around July 31, 2020, pending regulatory approvals from Nasdaq and TSX-V.
ESSA Pharma Inc. (Nasdaq: EPIX) has announced an underwritten public offering of its common shares. The company plans to utilize the proceeds for pre-clinical and clinical activities, R&D, and general corporate purposes. ESSA will grant underwriters a 30-day option to purchase an additional 15% of shares. The offering is contingent on market conditions and lacks guarantees on size or completion. Jefferies acts as the sole book-running manager, while Oppenheimer & Co. is the lead manager. The offering is subject to customary closing conditions and regulatory approvals.
ESSA Pharma Inc. (Nasdaq: EPIX) announced the first patient has been dosed in a Phase 1 clinical trial for EPI-7386, targeting metastatic castration-resistant prostate cancer (mCRPC) patients who have failed standard treatments. This small molecule inhibitor aims to demonstrate safety and tolerability while exploring its pharmacokinetic and anti-tumor effects. Approximately 18 patients will participate in the dose escalation phase, with further expansion expected. CEO David Parkinson highlighted this milestone as a step towards offering new treatment options for mCRPC patients.
